Research has suggested that TB-500 may:
- reduce inflammation within the cell
- hasten the recovery of damaged tissues
- delay or mitigate the onset of bacterial threats
Nevertheless, there is much contradictory information on the internet about properly managing this substance within a research setting. The key properties and mechanism of action of TB-500 are outlined in this detailed guide, which also includes scientific literature. In addition, we disclose the highest quality source for research-grade TB-500 at the end.
TB-500 Peptide: What is it?
A peptide, TB-500, has 43 amino acids. This protein is a synthetic analog of thymosin beta-4, an endogenous protein in animal cells encoded by the TMSB4X gene. Among the many vital biological processes that thymosin beta-4 is hypothesized to control are:
- Decreased irritation
- Renewal of the blood cell pool
- Enhanced cellular immunity
- Quicker healing of wounds
Researchers are investigating whether TB-500 may speed up the healing process – the thymus gland normally produces thymosin beta-4 in response to damage.
TB-500 Peptide: Mechanism of Action
The overexpression of a cellular protein known as “Actin” is the primary process by which TB-500 is believed to exert its potential. Actin is critical for maintaining cellular structural and functional integrity, particularly in muscle cells. Because of this, TB-500 has sparked speculation among scientists that it may improve muscular flexibility, speed up the healing process after tissue damage, and promote the creation of new cells. Incredibly mobility TB-500 is a result of its small molecular weight. Research on animals has indicated that TB-500 may increase Actin levels selectively at damage sites.
TB-500 Peptide Potential
Several statistically significant impacts of thymosin beta-4 have been speculated on in studies, including animal models. Here are the main points of these impacts:
TB-500 Peptide and the Heart
Researchers used cardiac cells in an in vitro investigation to determine if Thymosin Beta-4 might help mend heart damage. Specifically, Thymosin Beta-4 appeared to have prevented the death of heart cells while also stimulating vessel formation.
One study finding supported this result in research models after ST-elevation myocardial infarction (STEMI). This pilot research study suggested that STEMI research models presented with autologous thymosin β4 (Tβ4) before endothelial progenitor cells seemed to have better left ventricular function and physical capacity six months after the operation.
More follow-up is necessary after this result to draw any inferences about the use of TB-500 or similar chemicals in cell therapy studied under laboratory conditions for tissue healing.
TB-500 Peptide and Traumatic Brain Injury (TBI)
Researchers in 2012 speculated that rats suffering from traumatic brain damage or injury (TBI) made a speedy cognitive recovery following TB-500 exposure. Thymosin Beta-4-rats suggested functional recovery six hours after damage, and new brain cells and blood vessels formed as early as twenty-four hours after injury.
TB-500 Peptide and the Eyes
Experimental studies using Thymosin Beta-4 in the context of eye injury began as early as 2007. The following are examples of circumstances evaluated by the researchers:
- Myopia caused by diabetes
- Recovery time after cataract surgery
- Tears
- Chemical burns
A Phase II study indicated the potential of Thymosin beta-4 eye drops in alleviating severe dry eye conditions.
TB-500 Peptide and Wounds
Thymosin Beta-4’s anti-wounding potential was suggested in preclinical animal trials using various rat and mouse types, including those that had been presented with steroids, were elderly, or had diabetes. The same analysis also looked at two ulcer-related Phase II studies.
Thymosin Beta-4 test models appeared to recover one month more quickly than placebo-treated ones. The writers also speculated thymosin beta-4’s potential to halt further inflammation and infection. The anti-inflammatory potential of Thymosin Beta-4 needs further investigation in research settings.
TB-500 Peptide and Joints
The scientific consensus on this remains unclear, even when testing on animals. According to a 2017 review on rheumatoid arthritis, a small amount of research has indicated that thymosin beta-4 may have anti-inflammatory potential.
Nevertheless, some research indicated that Thymosin Beta-4 might enhance the release of pro-inflammatory substances. Even while RA research models consistently have elevated Thymosin Beta-4 expression in their joint fluid, the positive or negative effects of this finding remain unclear. This suggests that more investigation into this field could be necessary.
TB-500 Peptide and Ligaments
Research conducted on rats purported that thymosin beta-4 may have had “potential clinical [study] in repairing ligaments.” Thymosin Beta-4 was hypothesized to substantially improve biomechanical function in mice after medial collateral ligament (MCL) transects were performed once monthly.
In addition, the rats’ collagen fibers were reported to seem homogeneous and widely distributed. This means that when an injury or wound has healed, normal mobility may be resumed since Thymosin Beta-4 is theorized to be an effective wound healer.
Researchers interested in further investigating this peptide’s potential are encouraged to visit the biotechpeptides.com website for the highest-quality research compounds.
References
[i] Tokura Y, Nakayama Y, Fukada S, et al. Muscle injury-induced thymosin β4 acts as a chemoattractant for myoblasts. J Biochem. 2011;149(1)
[ii] Goldstein AL. History of the discovery of the thymosins. Ann N Y Acad Sci. 2007 Sep;1112:1-13. Epub 2007 Jun 28. PMID: 17600284.
[iii] Shrivastava S, Srivastava D, Olson EN, et al. Thymosin beta4 and cardiac repair.Ann N Y Acad Sci. 2010;1194:87-96.
[iv] Zhu J, Song J, Yu L, Zheng H, Zhou B, Weng S, Fu G. Safety and efficacy of autologous thymosin β4 pre[1]treated endothelial progenitor cell transplantation in patients with acute ST segment elevation myocardial infarction: A pilot study. Cytotherapy. 2016 Aug;18(8):1037-1042. Epub 2016 Jun 7. PMID: 27288307.
[v] Xiong Y, Mahmood A, Meng Y, et al. Neuroprotective and neurorestorative effects of thymosin β4 treatment following experimental traumatic brain injury. Ann N Y Acad Sci. 2012;1270:51–58.
[vi] Sosne G, Qiu P, Kurpakus-Wheater M. Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent. Clin Ophthalmol. 2007;1(3):201– 207.
[vii] Sosne G, Dunn S, Crockford D, et al. Thymosin Beta 4 Eye Drops Significantly Improve Signs and Symptoms of Severe Dry Eye in a Physician[1]Sponsored Phase 2 Clinical Trial. Invest Ophthalmol Vis Sci. 2013;54(15):6033.
[viii] Treadwell T, Kleinman HK, Crockford D. The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients. Ann N Y Acad Sci. 2012;1270:37-44.